Subcutaneous Drug Delivery Market Size, Share, Opportunities, And Trends By Product Type (Prefilled syringes, Pen injector, Autoinjectors, Wearable injectors, Needle-free Injectors), By Application (Diabetes, Fertility, Oncology, Others), By End-Users (Hospitals and Clinics, Homecare Settings, Ambulatory Surgical Centers), And By Geography - Forecasts From 2025 To 2030

The subcutaneous drug delivery market is estimated at USD41.704 billion in 2025 and is anticipated to grow at a CAGR of 6.26% during the forecast period and reach USD56.503 billion in 2030.

The market for subcutaneous drug delivery devices is growing rapidly, primarily due to increasing demand for advanced minimally invasive solutions. The increase in the prevalence of chronic conditions such as CVD and diabetes, along with advancements in biological drug development, are transforming the modern healthcare landscape.

What are the Subcutaneous Drug Delivery Market drivers?

• The role of Drug-Device Systems in Chronic Disease Management is anticipated to fuel market growth in the projected period

Major global health challenges that arise from chronic diseases include asthma, multiple sclerosis, cardiovascular conditions, and diabetes. For instance, according to the Asthma and Allergy Foundation of America, asthma affects an estimated nearly 28 million people in the United States, or about 1 in 12. Within this population, nearly 23 million adults aged 18 years and older have ever been diagnosed with asthma.

Adopting drug-device delivery systems such as prefilled syringes and autoinjectors seems to be an encouraging step forward for improving a patient's outcome and diminishing healthcare burdens. The systems also help improve patient convenience while delivering accurate doses, thus saving on hospital visits for clinical procedures and filling significant gaps in managing chronic diseases.

The diabetes patient population has increased over the years, and companies have innovated and executed strategic initiatives to introduce advanced subcutaneous drug delivery devices. Prefilled syringes, especially insulin autoinjectors, have emerged as game-changing solutions, allowing patients to self-administer drugs efficiently and with minimal discomfort. For instance, IDF Diabetes Atlas (2021) says that 10.5% of the adult population, aged between 20 and 79 years, has diabetes and that nearly half of the cases are unaware that they are living with this condition. According to IDF projections, by 2045, 1 in 8 adults will be living with diabetes, increasing by 46% to an estimated 783 million. Over 90% of people living with diabetes have type 2 diabetes, largely driven by socio-economic, demographic, environmental, and genetic factors.

• The increasing geriatric population is expected to increase the demand for subcutaneous drug delivery in the coming years

Another key factor that has been fuelling the need for subcutaneous drug delivery devices is an increase in the geriatric population. Old age makes the individual vulnerable to chronic conditions such as diabetes, chronic obstructive pulmonary disease, respiratory infections, asthma, and heart disease. Global health studies reveal that a higher population above 65 is prone to these diseases. Effective and less invasive treatment would be necessary for this population group. For instance, according to the World Bank, demographic change is increasingly shaping our future. Globally, people aged 65 and over outnumber children under 5, and over two-thirds of them live in less developed countries. In less developed regions, there will be 1.25 billion people who are 65 and over in 2050, around 757 million more than in 2020.

Subcutaneous drug delivery systems fulfill the demand as these provide stable, user-friendly devices that assist in treating and diagnosing chronic diseases. This demographic pattern underscores the necessity of innovation in drug delivery systems. It is also crucial in reducing hospital admissions among the elderly and improving quality of life.

• Biologic Drug Development and Subcutaneous Administration

Biologic drugs have the characteristic advantage of high selectivity for their target disease mechanism. Subcutaneous delivery of these drugs achieves optimal efficacy; however, their development has correspondingly increased demand for delivery systems that can administer these advanced therapies. Subcutaneous delivery devices, including autoinjectors and wearable injectors, are thus being developed in response to these biologic-specific properties, like higher viscosities and dosing intervals.

Analysis of Subcutaneous Drug Delivery Market segments:

• By product type, the pen injector segment is anticipated to hold a major market share in the projected period

Pen injectors will continue to have the largest share of revenue as they are the most convenient, easy to use, and a major player in enhancing compliance by patients. This product category is widely used for diabetes management, insulin injections, and other chronic disease management. The growing prevalence of chronic diseases and constant improvements in pen injector technology are driving the market. Regulatory approvals are becoming increasingly common, and the increasing demand for home-based treatments increases the preponderance of pens within the subcutaneous drug delivery market, providing them with a strong market position. Additionally, increasing product launches will positively influence the pen injector segment in the coming years.

For instance, in February 2023, Phillips-Medisize, a Molex company and leader in the design and manufacture of drug delivery, diagnostic, and MedTech devices, expanded its product portfolio by introducing a disposable pen injector. Ideally suited for high-volume manufacturing, Phillips-Medisize offers pharmaceutical companies a familiar, highly competitive pen injector to facilitate faster, more efficient, and cost-effective market entry.

Geographical outlook of the Subcutaneous Drug Delivery Market:

• The North American subcutaneous drug delivery devices market is anticipated to hold a larger share in the projected period

The North American region is anticipated to hold a major market share due to the well-developed healthcare infrastructure, strong emphasis on innovation, and high-end technological capabilities. A healthy healthcare sector is enjoyed in North America due to highly developed medical facilities with superior care, making advanced drug delivery technologies available widely. In addition, heavy investment in regional research and development fuels continuous innovation of subcutaneous drug delivery devices, driving market growth and technological advancement.

The significant prevalence of chronic conditions, including diabetes, autoimmune disorders, and cardiovascular diseases, is a primary market driver in North America. The Centre for Disease Control and Prevention has estimated that nearly 29.7 million people in the United States, about 8.9% of the population, had diabetes in 2022, making an effective and accessible treatment option extremely important. Devices for subcutaneous drug delivery, including insulin pens, auto-injectors, and wearable injectors, are thus becoming indispensable management tools for such chronic conditions. These devices are far more convenient, precise, and patient-friendly drug administration, particularly for those in need of continuing, long-term treatments. With an aging population and the increasing prevalence of chronic diseases, the market for these devices is likely to expand even more, cementing North America's position as a leader in the global subcutaneous drug delivery market.

Key Developments in the Subcutaneous Drug Delivery Market:

• In April 2024, Ypsomed partnered with Ten23 Health, a global Swiss contract development and manufacturing organization. This partnership aims to advance the commercialization of the YpsoDose wearable injector for subcutaneous self-injection of large-volume doses. The Ten23 drug development, filling, and device assembly will significantly contribute to the product offering.

Subcutaneous Drug Delivery Market Scope:

Report Metric	Details
Subcutaneous Drug Delivery Market Size in 2025	US$41.704 billion
Subcutaneous Drug Delivery Market Size in 2030	US$56.503 billion
Growth Rate	CAGR of 6.26%
Study Period	2020 to 2030
Historical Data	2020 to 2023
Base Year	2024
Forecast Period	2025 – 2030
Forecast Unit (Value)	USD Billion
Segmentation	Product Type Application End-Users Geography
Geographical Segmentation	North America, South America, Europe, Middle East and Africa, Asia Pacific
List of Major Companies in the Subcutaneous Drug Delivery Market	Gerresheimer AG Ypsomed AG Medtronic Plc Sanofi Novo Nordisk
Customization Scope	Free report customization with purchase

 

Subcutaneous Drug Delivery Market is analyzed into the following segments:

• By Product Type:
  • Prefilled syringes
  • Pen injector
  • Autoinjectors
  • Wearable injectors
  • Needle-free Injectors
• By Application:
  • Diabetes
  • Fertility
  • Oncology
  • Others
• By End-Users:
  • Hospitals and Clinics
  • Homecare Settings
  • Ambulatory Surgical Centers
• By Geography:
  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • Israel
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Indonesia
    • Thailand
    • Others

---

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base and Forecast Years Timeline

1.8. Key Benefits for the Stakeholders

2. RESEARCH METHODOLOGY  

2.1. Research Design

2.2. Research Process

3. EXECUTIVE SUMMARY

3.1. Key Findings

3.2. Analyst View

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Supplier

4.3.2. Bargaining Power of Buyers

4.3.3. The Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

5. SUBCUTANEOUS DRUG DELIVERY MARKET BY PRODUCT TYPE

5.1. Introduction

5.2. Prefilled syringes

5.3. Pen injector

5.4. Autoinjectors

5.5. Wearable injectors

5.6. Needle-free Injectors

6. SUBCUTANEOUS DRUG DELIVERY MARKET BY APPLICATION

6.1. Introduction

6.2. Diabetes 

6.3. Fertility

6.4. Oncology

6.5. Others

7. SUBCUTANEOUS DRUG DELIVERY MARKET BY END-USERS

7.1. Introduction

7.2. Hospitals and Clinics 

7.3. Homecare Settings

7.4. Ambulatory Surgical Centers

8. SUBCUTANEOUS DRUG DELIVERY MARKET BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. USA

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. UK

8.4.2. Germany

8.4.3. France

8.4.4. Italy

8.4.5. Others

8.5. Middle East and Africa

8.5.1. Saudi Arabia

8.5.2. Israel

8.5.3. Others 

8.6. Asia Pacific

8.6.1. Japan

8.6.2. China

8.6.3. India

8.6.4. South Korea

8.6.5. Indonesia

8.6.6. Thailand

8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES

10.1. Gerresheimer AG

10.2. Ypsomed AG

10.3. Medtronic Plc

10.4. Sanofi

10.5. Novo Nordisk

10.6. Becton, Dickinson and Company

10.7. Elcam Medical Group

10.8. Unilife Corporation

10.9. Insulet Corporation

10.10. Eli Lilly and Company

Gerresheimer AG

Ypsomed AG

Medtronic Plc

Sanofi

Novo Nordisk

Becton, Dickinson and Company

Elcam Medical Group

Unilife Corporation

Insulet Corporation

Eli Lilly and Company